CXCL9 and neoplasm: The evidence strongly suggests that EP4 antagonist therapy increases the infiltration of effector CD8+ T cells into the tumor through the active production of chemokines CXCL9 and 10 from the DCs in tumors corresponding to the restoration of NK cell functions by EP4 signal inhibition (Figure 1).